Ariceum Therapeutics has established a subsidiary in Basel. According to a press release, the Chief Medical Officer was at the same time named as Germo Gericke from Novartis. The company specializing in nuclear medicine with headquarters in Berlin was supported in its settlement in Switzerland by Basel Area Business & Innovation.
According to information from Ariceum’s CEO Manfred Rüdiger, the aim of opening the new subsidiary in Basel is to expand the team “to build a global development hub for Ariceum”. He adds that Germo Gericke is bringing a wealth of experience in the area of radiopharmaceutical therapy and that he will lead and develop the team for clinical development and operational processes from the new subsidiary in Basel.
The new Chief Medical Officer Gericke commented: “Basel is at the heart of the European Life Sciences industry. It offers a well-connected, business-friendly environment and great networking opportunities thanks to the cluster of sector activity in the area.” He added that the city’s central location attracts talent from all over Europe and beyond.
Gericke is coming from Advanced Accelerator Applications (AAA), a Novartis company that develops radioligand therapies and imaging radioligands for oncology indications. He was Chief Medical Officer and Head of Research and Development. According to a press release, Gericke has built a global R&D organization for radioligand therapies.
